A never-before-reported mutation in the CD46 gene was found to contribute to the development of atypical hemolytic uremic syndrome (aHUS)…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Pericardial effusion — a potentially life-threatening disorder marked by the buildup of fluid around the heart — can affect people…
Atypical hemolytic uremic syndrome (aHUS) can occur concurrently with disseminated intravascular coagulation (DIC), a blood disorder marked by similar…
More than half of Chinese children with atypical hemolytic uremic syndrome (aHUS) have self-reactive antibodies targeting complement factor H,…
A woman in Italy developed atypical hemolytic uremic syndrome (aHUS) as a result of a blood cancer, which resolved…
Inflammation of the pancreas, known as pancreatitis, can occur alongside the rare disease atypical hemolytic uremic syndrome (aHUS) —…
Soliris (eculizumab) helped control atypical hemolytic uremic syndrome (aHUS) in a patient whose symptoms included seizures…
Plasma exchange therapy followed by treatment with Soliris (eculizumab) was effective at managing atypical hemolytic uremic syndrome (aHUS)…
Epysqli (eculizumab-aagh), a biosimilar of Soliris (eculizumab), is now available for patients in the U.S., according to an announcement…
A woman with lupus in her early 30s, who developed atypical hemolytic uremic syndrome (aHUS) after pregnancy, was not…